Dr. Albert Friesen reports

MEDICURE ANNOUNCES CLOSING OF PURCHASE AGREEMENT FOR THE ACQUISITION OF GATEWAY MEDICAL PHARMACY

Further to Medicure Inc.'s news release on Feb. 18, 2025, through its wholly owned United States subsidiary Medicure Pharma Inc., the company has closed on the acquisition of 100 per cent of Gateway Medical Pharmacy Inc. from an arm's-length third party.

As previously disclosed, the acquisition of Gateway aligns with Medicure's strategic plan for the expansion of the company's direct-to-consumer pharmacy business, and positions Medicure to accelerate its growth of Zypitamag and its other products and services.

Medicure did not require any financing or acquire any debt as part of the transaction, and no finder fees were paid by Medicure.

About Medicure Inc.

Medicure is a company focused on the development and commercialization of pharmaceuticals and health care products for patients and prescribers in the United States market. The present focus of the company is the marketing and distribution of Aggrastat (tirofiban hydrochloride) injection and Zypitamag (pitavastatin) tablets in the United States, where they are sold through the company's U.S. subsidiary, Medicure Pharma. Medicure also operates Marley Drug Inc., a pharmacy subsidiary servicing all 50 states, Washington and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery.

About Gateway Medical Pharmacy Inc.

Independently owned, Gateway is located in Portland, Ore., in a medical office building near major transportation lines and multiple health care clinics and centres. In addition to regular customers, the pharmacy services multiple long-term care facilities and provides non-sterile compounding services.

We seek Safe Harbor.